 multicenter trial ursodiol treatment primary biliary cirrhosis UDCA-PBC Study Group BACKGROUND primary biliary cirrhosis hepatic lesions part intracellular accumulation toxic endogenous bile acids Preliminary work administration ursodiol ursodeoxycholic acid hydrophilic bile acid hepatotoxicity improvement condition patients primary biliary cirrhosis METHODS two-year multicenter double-blind trial efficacy ursodiol placebo Patients biopsy-proved primary biliary cirrhosis ursodiol mg kilogram body weight day placebo Treatment failure doubling bilirubin levels mumol liter occurrence severe complication adverse reaction RESULTS Treatment patients ursodiol group placebo group Cox regression model single patient group minor adverse effects years treatment proportion patients overt disease ursodiol group patients ursodiol significant improvements serum levels bilirubin alkaline phosphatase alanine aminotransferase aspartate aminotransferase gamma-glutamyltransferase cholesterol IgM antimitochondrial-antibody titer Mayo risk score Follow-up analysis liver-biopsy specimens significant improvement mean histologic score characteristic histologic features fibrosis group CONCLUSIONS Ursodiol safe effective treatment primary biliary cirrhosis